JP2024529009A - セロトニン再取り込み阻害剤離脱症候群の治療 - Google Patents

セロトニン再取り込み阻害剤離脱症候群の治療 Download PDF

Info

Publication number
JP2024529009A
JP2024529009A JP2024506806A JP2024506806A JP2024529009A JP 2024529009 A JP2024529009 A JP 2024529009A JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024529009 A JP2024529009 A JP 2024529009A
Authority
JP
Japan
Prior art keywords
escitalopram
gentisate
subject
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529009A5 (enExample
Inventor
マーク・ヘースルトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2024529009A publication Critical patent/JP2024529009A/ja
Publication of JP2024529009A5 publication Critical patent/JP2024529009A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
JP2024506806A 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療 Pending JP2024529009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (2)

Publication Number Publication Date
JP2024529009A true JP2024529009A (ja) 2024-08-01
JP2024529009A5 JP2024529009A5 (enExample) 2025-06-19

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506806A Pending JP2024529009A (ja) 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療

Country Status (8)

Country Link
US (1) US20240277654A1 (enExample)
EP (1) EP4366726A1 (enExample)
JP (1) JP2024529009A (enExample)
KR (1) KR20240117521A (enExample)
CN (1) CN118284414A (enExample)
AU (1) AU2022308198A1 (enExample)
CA (1) CA3227324A1 (enExample)
WO (1) WO2023281406A1 (enExample)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
PT1635875E (pt) 2003-06-26 2008-12-09 Psivida Inc Sistema de libertação de um fármaco com gelificação in situ
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
AU2009255675B2 (en) 2008-06-03 2014-10-09 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
PL2323623T3 (pl) 2008-08-12 2017-04-28 Novartis Ag Kompozycje farmaceutyczne
AU2009301646B2 (en) 2008-10-10 2013-09-05 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
EP2379064B1 (en) 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
WO2010105093A2 (en) 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
ES2699692T3 (es) 2010-01-04 2019-02-12 Mapi Pharma Ltd Sistema de depósito que comprende acetato de glatiramer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
MX347090B (es) 2010-12-29 2017-04-11 Medincell Composiciones de suministro de farmacos biodegradables.
RS60051B1 (sr) 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
EP2770983B1 (en) 2011-10-24 2017-04-19 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
RU2672596C2 (ru) 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
RU2658004C2 (ru) 2013-06-20 2018-06-19 Фарматен С.А. Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram

Also Published As

Publication number Publication date
CA3227324A1 (en) 2023-01-12
KR20240117521A (ko) 2024-08-01
WO2023281406A1 (en) 2023-01-12
AU2022308198A1 (en) 2024-02-01
US20240277654A1 (en) 2024-08-22
CN118284414A (zh) 2024-07-02
EP4366726A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US12496300B2 (en) Methods of treating acute depression and anxiety
EP3064206B1 (en) Treatment of huntington's disease using laquinimod
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
AU2014261329B2 (en) Fenfluramine for use in the treatment of dravet syndrome
US11813247B2 (en) NK-1 antagonist compositions and methods for use in treating depression
AU2018364659A1 (en) Ganaxolone for use in treating genetic epileptic disoders
JP2024010018A (ja) うつ病を治療するための組成物および方法
EP4366726A1 (en) Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2024102802A1 (en) Zelatriazin for the treatment of depression
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
US20240100012A1 (en) Pharmaceutical dosage form
Van Schoor Antihistamines: a brief review: clinical
TW202541796A (zh) 用於治療失樂症的組成物及方法
WO2025096942A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia
AU2024369511A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
US20220071976A1 (en) Domperidone compositions and methods for treating depression
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
TW200800160A (en) Prophylactic or therapeutic agent for sleep disorder
CN101304746A (zh) 氟班色林在治疗绝经前性欲障碍中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250611